Last reviewed · How we verify
Desobesi (FENPROPOREX)
At a glance
| Generic name | FENPROPOREX |
|---|---|
| Drug class | fenproporex |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| Annual revenue | 172 |
Approved indications
- Obesity
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Desobesi CI brief — competitive landscape report
- Desobesi updates RSS · CI watch RSS